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Abstract
Introduction Sepsis activates the coagulation system and
frequently causes hypercoagulability, which is not detected by
routine coagulation tests. A reliable method to evaluate
hypercoagulability is thromboelastography (TEG), but this has
not so far been used to investigate sepsis-induced
hypercoagulability. Antithrombin (AT) in plasma of septic
patients is decreased, and administration of AT may therefore
reduce the acquired hypercoagulability. Not clear, however, is to
what extent supraphysiologic plasma levels of AT decrease the
acute hypercoagulability in septic patients. The present study
investigates the coagulation profile of septic patients before and
during four day high-dose AT therapy.
Methods Patients with severe sepsis were randomly assigned
to receive either 6,000 IU AT as a bolus infusion followed by a
maintenance dose of 250 IU/hour over four days (n = 17) or
placebo (n = 16). TEG, platelet count, plasma fibrinogen levels,
prothrombin time and activated partial thromboplastin time were
assessed at baseline and daily during AT therapy.
Results TEG showed a hypercoagulability in both groups at
baseline, which was neither reversed by bolus or by
maintenance doses of AT. The hypercoagulability was mainly
caused by increased plasma fibrinogen, and to a lesser extent
by platelets. Plasmatic coagulation as assessed by the
prothrombin time and activated partial thromboplastin time was
similar in both groups, and did not change during the study
period.
Conclusion The current study shows a distinct
hypercoagulability in patients suffering from severe sepsis,
which was not reversed by high-dose AT treatment over four
days. This finding supports recent data showing that modulation
of coagulatory activation in septic patients by AT does not occur
before one week of therapy. 
Trial registration: Current Control Trials ISRCTN22931023
Introduction
Sepsis activates the host's defense system by initiating the
release of a complex network of proinflammatory and anti-
inflammatory cytokines. The septic process frequently induces
intravascular coagulation, which activates endogenous antico-
agulants and the fibrinolytic system. As a consequence coag-
ulation inhibitors are consumed, and fibrinolysis is inhibited by
the production of plasminogen activator inhibitor 1 [1]. Hyper-
coagulability develops in septic patients, resulting in enhanced
thrombin generation, thrombin activation, and fibrin formation.
Routine coagulation tests, such as the prothrombin time and
the activated partial thromboplastin time, do not reflect this
state, as they are sensitive for coagulation defects not for
hypercoagulability [2]. A reliable method to evaluate hyperco-
agulability is thromboelastography (TEG) [3-6]. No study,
however, has so far investigated hypercoagulability in patients
suffering from sepsis with the use of TEG.
Physiologically, three main inhibitors are involved in the host
defense against the activation of coagulation: the tissue factor,
the protein C system, and antithrombin (AT). The concentra-
tion of AT in plasma of septic patients is decreased, and this
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is a predictor of an unfavorable prognosis [7]. Open-labeled
and phase II trials showed that administration of AT concen-
trates may improve the outcome of sepsis due to the reduction
of hypercoagulability and due to the anti-inflammatory proper-
ties of AT [8-10]. One large phase III study, however, failed to
improve the outcome of septic patients, perhaps due to study
biases or drug interaction [11,12].
In studies using high-dose AT therapy in septic patients, either
the effects of AT on coagulation have not been described in
detail [8,9,11] or coagulation markers, such as protein C and
prothrombin activity, have been investigated [10,13]. To what
extent supraphysiologic levels of AT decrease the acute hyper-
coagulability in septic patients is therefore unknown.
We hypothesized that TEG can assess which patients suffer-
ing from sepsis show hypercoagulability, and that high-dose
AT therapy may reduce this hypercoagulability. Accordingly,
we investigated TEG, plasmatic coagulation tests, plasma lev-
els of fibrinogen, and platelet counts in septic patients before
and during high-dose AT therapy.
Methods
This study was performed as an addition to a double-blind, pla-
cebo-controlled, multicenter clinical phase III trial in patients
with severe sepsis (the KyberSept trial) [11]. In accordance
with the Institutional Review Board of the University of Vienna,
patients were included in the study and their written informed
consent was obtained after adequate recovery.
Patients suffering from severe sepsis were assigned by a tele-
phone randomization service to receive either AT (Aventis
Behring GmbH, Marburg, Germany) (n = 17) or placebo solu-
tion (1% human albumin) (n  = 16). The treatment group
received 6,000 IU AT as a bolus infusion followed by a main-
tenance dose of 250 IU/hour over four days. Standard therapy,
such as antimicrobial therapy, respiratory or hemodynamic
support, and fluid administration, was not influenced by the
study and was at the physicians' discretion.
Patients with suspected severe sepsis were enrolled if they
fulfilled the following criteria within a six hour time window prior
to randomization: clinical evidence of sepsis with a suspected
source of infection, body temperature (rectally or core)
>38.5°C or <35.5°C, and leukocyte count >10,000/μl or
<3,500/μl. Additionally, three out of the following six criteria
had to be met: heart rate >100 beats/min, tachypnea >24
breaths/min or mechanical ventilation because of septic indi-
cation, systolic blood pressure <90 mmHg despite sufficient
fluid replacement or the need for vasoactive agents to maintain
systolic blood pressure >90 mmHg, thrombocytopenia with
platelet counts <100,000/ml, elevated lactate levels or meta-
bolic acidosis (that is to say, pH <7.3 or base excess above -
10 mmol/l) not secondary to respiratory alkalosis, and oliguria
with urine output <20 ml/hour despite sufficient fluid replace-
ment. The exclusion criteria were, among others [11], preg-
nancy and/or breastfeeding, presence of a condition other
than sepsis anticipated to be fatal within 28 days, history of
hypersensitivity to the study medication, treatment with an AT
concentrate within the previous 48 hours, treatment with
heparin exceeding 10,000 IU/day low-molecular-weight
heparin, known bleeding disorders or ongoing massive surgi-
cal bleedings, nonsteroidal anti-inflammatory drugs in anti-
inflammatory doses within the previous two days, platelet
count <30,000 ml, pre-existing dialysis-dependent renal fail-
ure, end-stage liver disease, or enrollment in another clinical
trial within the previous 30 days.
Routine laboratory measurements were carried out as usual.
The coagulation profile was assessed at least three times a
day during treatment with the study medication. Routine AT
measurements during the first 14 days of the study were not
performed, to ensure the double-blinded fashion of the study.
Samples for determination of AT (activity and antigen) were
drawn before the bolus infusion, 24 hours after the start of
bolus infusion, and then daily. These samples were centri-
fuged at 4°C and stored at -80°C for central measurements.
The AT activity was provided by Aventis Behring GmbH after
trial finalization. The platelet count, plasma fibrinogen levels,
prothrombin time, and activated partial thromboplastin time
were assessed at baseline and three times daily.
In addition to standard coagulation tests we performed two
thromboelastograph scans before the bolus infusion and then
daily (TEG®; Haemoscope, Skokie, IL, USA), each using 300
μl whole blood recalcified with 40 μl of 0.645% CaCl2. TEG
measurements were performed after incubating the blood
samples with heparinase, to exclude heparin effects on TEG.
The antibody fragment abciximab (ReoPro®; Centocor, Lei-
den, The Netherlands) was added to one assay to evaluate
platelet function [14,15]. TEG permits a reliable, global
assessment of hemostatic function correlating to routine coag-
ulation tests and, most importantly, to postoperative blood loss
and the incidence of thrombotic complications [5,16]. Liquid
whole blood transmits little or no torque in TEG, producing no
amplitude on the TEG tracing even in blood samples with high
viscosity [17]. As the blood clots, fibers composed of fibrin
and platelets form, producing an increasing amplitude. Plate-
lets provide a phospholipid surface for coagulation reactions
in the standard TEG tracing and thus promote the formation of
fibrin [17]. Furthermore, platelets bind to fibrinogen and mod-
ulate the viscoelastic properties of the clot via the platelet sur-
face receptor glycoprotein IIb/IIIa [15]. The glycoprotein IIb/IIIa
receptor can be sufficiently inhibited by the antibody-fragment
abciximab. Fibrinogen is soluble until thrombin binds to the
central region, which produces proteolysis at the N-terminus,
releasing fibrinopeptide A and B and fibrin monomer. This
release process exposes other regions of the molecule to
interact with other activated fibrin molecules for polymerization
of the fibrin network. The end point of this cascade is fibrin.Available online http://ccforum.com/content/10/6/R160
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The reaction time (r), coagulation time (k), alpha angle (α),
maximum amplitude (MA), and abciximab MA were assessed.
Values for r and k are expressed in millimeters – as the chart
speed is 2 mm/min, the time in minutes is equal to the distance
in millimeters divided by two (normal ranges: r = 10–19 mm, k
= 4–10 mm). The α value measures the speed of fibrin build-
up and cross-linking, which resembles speed of clot strength-
ening (normal range: α = 44–56°). The MA measures the max-
imal clot strength, which is dependent on platelet function and,
to a lesser extent, on fibrinogen level (normal range: MA = 50–
64 mm). Whereas the correlation between standard MA and
fibrinogen levels is usually weak, the modification of TEG with
the antibody fragment abciximab results in a good correlation
between fibrinogen levels and abciximab-modified MA [15].
Because the resulting MA of the abciximab-modified TEG is an
estimation of the contribution of fibrinogen to clot strength, the
difference of the standard MA and the abciximab-modified MA
primarily reflects platelet function [15]. The TEG tracing of
hypercoagulable blood typically shows a shorter reaction time,
with a higher MA and a steeper α value than normal.
Statistical analysis
An unpaired Mann–Whitney nonparametric test with Bonfer-
roni correction for multiple testing was performed to compare
for differences between the AT and placebo group. P < 0.05
was considered statistically significant, and all data are pre-
sented as the mean ± standard deviation or as the median
(minimum–maximum) unless otherwise indicated.
Results
Demographic data were similar among the groups (Table 1).
None of the patients was on corticosteroid replacement ther-
apy, as this was not a standard therapy for sepsis in our insti-
tution at that time. Two patients in each group received
continuous hemofiltration during the AT treatment. All patients
received noradrenalin, despite adequate volume resuscitation.
Coagulation profiles as assessed by TEG showed a hyperco-
agulability in both groups of the included septic patients at
baseline (Table 2). This hypercoagulability comprised all
measured TEG parameters, since r and k were decreased and
α and MA were increased compared with normal values. Both
plasmatic and cellular hemostasis therefore showed hyperre-
activity. High doses of AT did not reverse this hypercoagulabil-
ity, and caused only a slight increase in the reaction time
(Table 2). During the four days of treatment with AT the hyper-
coagulability assessed by TEG remained similar, although
plasma levels of AT reached supranormal values.
We assessed the contribution of platelets and fibrinogen to
hypercoagulability using the abciximab-modified MA. Hyper-
coagulability was mainly caused by the activity of plasma fibrin-
ogen. The platelets also showed hyperreactivity, but
contributed to hypercoagulability to a lesser extent than did
plasma fibrinogen.
Plasmatic coagulation as assessed by the prothrombin time
and the activated partial thromboplastin time was similar in
both groups, and did not change during the study period. In
contrast to the TEG parameters, the plasmatic coagulation
tests were at the lower range of normal values or were even
prolonged.
Discussion
We investigated the effects of a four day treatment with high
doses of AT on coagulation in septic patients. Our study
shows a distinct hypercoagulability in patients suffering from
sepsis as assessed by TEG. This hypercoagulability was not
influenced by high doses of AT administered over four days,
and treatment with AT influenced neither TEG parameters nor
standard coagulation tests.
The high sensitivity of TEG to hypercoagulability has been
described in numerous studies [3-5,15], and it is not surpris-
Table 1
Demographic data of patients suffering from sepsis receiving either placebo or high-dose antithrombin therapy
Placebo Antithrombin
Number of patients (n) 16 17
Age (years) 56 ± 17 51 ± 19
Height (cm) 175 ± 4 169 ± 9
Weight (kg) 80.7 ± 22.5 75.9 ± 22.4
4-day survival rate (n) 16 16
28-day survival rate (n)1 1 1 2
Acute Pathophysiology and Chronic Health Evaluation II score 52 ± 9.5 53 ± 12.6
Low-molecular-weight heparin at inclusion (IU/day) 6042 ± 1982 6388 ± 2205
Data presented as the mean ± standard deviation or n.Critical Care    Vol 10 No 6    Gonano et al.
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ing that we found a distinct hypercoagulability in patients suf-
fering from severe sepsis. TEG has not so far been used to
investigate sepsis-related hypercoagulability, but coagulation
disturbances leading to hypercoagulability during sepsis are
well described [1].
Surprising is the finding that high doses of AT hardly influence
hypercoagulability, as assessed by TEG, in septic patients.
The sensitivity of TEG to plasma levels of AT has been shown
recently [18,19]. Hypercoagulability is attenuated in TEG
when exogenous AT is administered to reach normal ranges of
AT. It is remarkable, therefore, that the high-dose treatment
with AT over four days, which caused supranormal plasma lev-
els of AT, hardly affected the TEG variables.
High-dose AT therapy in septic patients has been investigated
in several studies. Although phase II trials showed that admin-
istration of AT concentrates may improve the outcome of sep-
sis [8-10], the treatment with AT for four days did not reduce
the overall 28-day mortality rates compared with placebo in a
large phase III study [11]. Besides other factors [12], an insuf-
ficient dosage and duration of AT therapy could have been
responsible for the negative results. In a recent study, pro-
longed duration of AT therapy guided by the actual activity,
instead of a predefined dose, resulted in an effective modula-
tion of coagulatory activation [13]. The effects of AT were
thereby not evident until one week of therapy. Additionally, the
selection of septic patients who may profit from AT therapy
seems to be important. Patients with AT activity below 70% or
patients undergoing continuous renal replacement therapies
may profit most [20]. Our data seem to confirm these findings,
as we did not find alterations of coagulation parameters during
the four day treatment with high doses of AT in a population of
septic patients not selected by AT activity or a need for renal
replacement therapy.
The patients in the AT group were well matched to the control
group concerning demographic data, coagulation parameters,
and the extent of organ failure. The main finding of this study
results from comparison of coagulation profiles within the AT
group, which showed mild attenuation of hypercoagulability
after bolus application of AT and no differences in the later
time course. The control group was investigated to show the
time course of hypercoagulability in septic patients without AT
therapy. The finding that coagulation profiles do not differ
between the AT group and the placebo group from the second
day of treatment may imply that the selected dose of AT was
not sufficient to reduce hypercoagulability and/or that a four
day treatment is insufficient.
The abciximab-modified MA showed that hypercoagulability
was mainly caused by the activity of plasma fibrinogen, and to
a lesser extent by platelet hyperreactivity. Owing to the com-
plex inclusion/exclusion criteria of the KyberSept trial, we may
have excluded the patients who might have profited most from
AT therapy. A recent retrospective analysis of the KyberSept
trial actually showed that high-dose AT without concomitant
heparin in septic patients with overt and nonovert dissemi-
nated intravascular coagulation resulted in a mortality reduc-
tion [21]. Many clinicians in our center administered AT when
the AT level was below 40%, and, in addition, the indications
for continuous renal replacement therapies with heparin anti-
coagulation are liberal. Both interventions led to the exclusion
of numerous patients, most of whom had severe coagulation
abnormalities. The platelet count was actually normal in most
patients at inclusion. We therefore assume that we excluded
patients with the strongest platelet activation, whereas the
Table 2
Coagulation parameters during the study
At baseline After bolus application At end of treatment period
Placebo Antithrombin Placebo Antithrombin Placebo Antithrombin
Prothrombin time (%) 70 (38–95) 60 (38–103) 60 (39–84) 60 (38–82) 77 (5–10) 64 (5–9)
Activated partial thromboplastin time (s) 42 (27–53) 46 (33–60) 44 (32–67) 53 (34–77) 44 (29–74) 47 (34–95)
Fibrinogen (mg/dl) 587 (262–821) 557 (229–841) 595 (283–770) 505 (313–704) 622 (115–842) 538 (200–868)
Platelet count (1,000/ml) 225 (86–581) 179 (71–742) 170 (81–358) 154 (61–730) 199 (63–418) 115 (14–475)
Antithrombin (%) 68 (31–113) 55 (27–99) 54 (22–108) 110* (43–350) 86 (29–87) 141* (110–149)
Reaction time (mm) 7 (6–15) 9 (6–16) 8 (5–15) 11 (7–25) 8 (5–19) 11 (8–18)
Coagulation time (mm) 3 (2–4) 3 (2–8) 3 (2–4) 3 (2–7) 2 (1–8) 4 (3–10)
Alpha angle (°) 74 (64–80) 71 (50–80) 69 (64–81) 70 (36–79) 76 (43–81) 64 (46–76)
Maximum amplitude (mm) 69 (57–79) 66 (49–81) 66 (60–74) 70 (49–83) 71 (38–82) 72 (38–82)
Abciximab maximum amplitude (mm) 29 (15–49) 29 (13–49) 29 (23–45) 28 (12–45) 33 (14–48) 31 (7–48)
Data presented as the median (minimum–maximum). Normal ranges: prothrombin time = 75–140%, activated partial thromboplastin time = 27–
41 s, reaction time = 10–19 mm, coagulation time = 4–10 mm, alpha angle = 44–56°, maximum amplitude = 50–64 mm. *P ≤ 0.05 compared 
with placebo.Available online http://ccforum.com/content/10/6/R160
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fibrinogen levels were generally increased at inclusion (Table
1).
Low-dose low-molecular-weight heparin was given subcuta-
neously in the present study to prevent thromboembolic com-
plications, with similar dosing in both groups. As TEG is highly
sensitive to all types of heparin, either unfractionated heparin
or low-molecular-weight heparin [22], the TEG measurements
were performed after incubating the blood samples with hepa-
rinase, to exclude heparin effects on TEG. The effects of hepa-
rinase  per se are minor and, as all measurements were
performed in an identical manner, incubation with heparinase
should not have altered our results.
The limitation of the present study is the small number of
included patients. The main finding of the study, however, was
that AT therapy had hardly any effect on coagulation as
assessed by TEG. Although one could speculate that the dif-
ferences in TEG variables may become statistically significant
with more patients included, the clinical significance seems
questionable as TEG measurements both before and after
administration of the AT bolus show a distinct
hypercoagulability.
Conclusion
The current study shows a distinct hypercoagulability in
patients suffering from severe sepsis, which is not attenuated
by administration of high doses of AT over four days. This find-
ing supports recent data showing that prolonged duration of
AT therapy guided by the actual activity, instead of a prede-
fined dose, can result in the modulation of coagulatory activa-
tion after one week of therapy.
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